Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blocking the smell of smoke may curb the urge to light up

NCT ID NCT06191419

Symptom relief Sponsor: Tim McClintock Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests whether blocking the smell of cigarette smoke can reduce a smoker's desire to smoke. Participants wear a mask that delivers odor samples and rate how pleasant the smell is and how much they want to smoke. The goal is to see if odor blockers could become a new aid for smoking cessation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
odor blockers
What this could lead to
If successful, odor blockers could become a new tool to help smokers quit by reducing the urge triggered by cigarette smell.
What could go wrong
This is a small, early-stage study with only 27 participants. The odor blockers may not effectively reduce smoking urges or help with quitting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Apr 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Smoker Exclusion Criteria: * Non Smoker * Self reported inability to smell or taste

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Smoking behaviors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nicotine dependence Smoking Tobacco Smoking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Smoking behaviors Tobacco smoking

Contacts and locations

Locations

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.